Merus N.V. (MRUS): Price and Financial Metrics

Merus N.V. (MRUS): $23.05

-2.58 (-10.07%)

POWR Rating

Component Grades













Add MRUS to Watchlist
Sign Up

Industry: Biotech


of 506

in industry


  • Growth is the dimension where MRUS ranks best; there it ranks ahead of 71.78% of US stocks.
  • MRUS's strongest trending metric is Momentum; it's been moving down over the last 47 weeks.
  • MRUS's current lowest rank is in the Momentum metric (where it is better than 4.63% of US stocks).

MRUS Stock Summary

  • For MRUS, its debt to operating expenses ratio is greater than that reported by merely 8.39% of US equities we're observing.
  • MRUS's price/sales ratio is 25.27; that's higher than the P/S ratio of 91.79% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for MRUS comes in at -19.72% -- higher than that of just 13.34% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Merus NV, a group of peers worth examining would be VYGR, STRO, CHRS, SVRA, and CTMX.
  • Visit MRUS's SEC page to see the company's official filings. To visit the company's web site, go to

MRUS Valuation Summary

  • In comparison to the median Healthcare stock, MRUS's price/sales ratio is 589.47% higher, now standing at 26.2.
  • MRUS's price/sales ratio has moved down 39.5 over the prior 64 months.
  • MRUS's EV/EBIT ratio has moved down 3.7 over the prior 64 months.

Below are key valuation metrics over time for MRUS.

Stock Date P/S P/B P/E EV/EBIT
MRUS 2021-08-31 26.2 4.6 -11.3 -8.0
MRUS 2021-08-30 26.1 4.6 -11.3 -7.9
MRUS 2021-08-27 26.7 4.7 -11.5 -8.2
MRUS 2021-08-26 25.9 4.5 -11.2 -7.8
MRUS 2021-08-25 25.2 4.4 -10.9 -7.5
MRUS 2021-08-24 24.5 4.3 -10.6 -7.2

MRUS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MRUS has a Quality Grade of D, ranking ahead of 23.85% of graded US stocks.
  • MRUS's asset turnover comes in at 0.125 -- ranking 247th of 677 Pharmaceutical Products stocks.
  • IDXX, TEVA, and IMGN are the stocks whose asset turnover ratios are most correlated with MRUS.

The table below shows MRUS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.125 1 -4.520
2021-03-31 0.120 1 -2.933
2020-12-31 0.132 1 -2.684
2020-09-30 0.122 1 -2.459
2020-06-30 0.124 1 -1.944
2020-03-31 0.124 1 -1.710

MRUS Price Target

For more insight on analysts targets of MRUS, see our MRUS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $30.63 Average Broker Recommendation 1.22 (Strong Buy)

MRUS Stock Price Chart Interactive Chart >

Price chart for MRUS

MRUS Price/Volume Stats

Current price $23.05 52-week high $31.27
Prev. close $25.63 52-week low $11.19
Day low $23.00 Volume 119,361
Day high $25.16 Avg. volume 206,045
50-day MA $21.54 Dividend yield N/A
200-day MA $21.70 Market Cap 886.92M

Merus N.V. (MRUS) Company Bio

Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. The company was founded in 2003 and is based in Utrecht, Netherlands.

MRUS Latest News Stream

Event/Time News Detail
Loading, please wait...

MRUS Latest Social Stream

Loading social stream, please wait...

View Full MRUS Social Stream

Latest MRUS News From Around the Web

Below are the latest news stories about Merus NV that investors may wish to consider to help them evaluate MRUS as an investment opportunity.

Merus N.V. (MRUS) Reports Q2 Loss, Tops Revenue Estimates

Merus N.V. (MRUS) delivered earnings and revenue surprises of -18.33% and 58.06%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 6, 2021

Merus Announces Financial Results for the Second Quarter and Provides Business Update

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the second quarter that ended June 30, 2021 and provided a business update.

Intrado Digital Media | August 5, 2021

Earnings Preview: Merus N.V. (MRUS) Q2 Earnings Expected to Decline

Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 29, 2021

Merus N.V.: Merus Announces Publication in Nature Communications on MCLA-145''s Novel Mechanism of Action Promoting Tumor Immunity and Context Dependent T-Cell Costimulation

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 21, 2021. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics

FinanzNachrichten | July 21, 2021

Hedge Funds Are Crazy About Merus N.V. (MRUS)

The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the first quarter, which unveil their equity positions as of March 31st. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]

Yahoo | July 20, 2021

Read More 'MRUS' Stories Here

MRUS Price Returns

1-mo 3.74%
3-mo 5.98%
6-mo 11.35%
1-year 78.13%
3-year 21.32%
5-year 116.23%
YTD 31.49%
2020 24.50%
2019 0.57%
2018 -27.84%
2017 -8.10%
2016 N/A

Continue Researching MRUS

Want to see what other sources are saying about Merus NV's financials and stock price? Try the links below:

Merus NV (MRUS) Stock Price | Nasdaq
Merus NV (MRUS) Stock Quote, History and News - Yahoo Finance
Merus NV (MRUS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9598 seconds.